Oncology Resource Group experts focus year-round on Emerging Immuno-Oncology to deliver cutting-edge competitive intelligence with unmatched depth, breadth and insight. ONCrg fills a critical gap in the drug industry to rigorously evaluate early stage I-O products that are not clearly being developed in a specific cancer type – before they leap-frog into late stage and/or combination trials that could rapidly change the competitive landscape.
Regina Cheung Ph.D.
Therapy Area Manager
Regina received a Ph.D. in Immunology from Stanford, and B.S. and M.S. degrees in mechanical engineering from Caltech and MIT. She successfully manages multiple hematology areas at ONCrg and brings together strong scientific, analytical, and managerial acumen to lead our I-O efforts.
Amanda Lanser, Ph.D.
Disease Area Analyst, Oncology
Amanda received her Ph.D. in Immunology from Harvard University where she studied the role of the immune system in epilepsy. She has additional experience in technology commercialization, business development and venture. Amanda’s valuable implications are derived from her passion and understanding of medical sciences, patient needs and commercial strategy.
Martin Fan, Ph.D.
Disease Area Analyst, ONCrg
Martin received a Ph.D. in Immunology from Harvard University where he studied immune regulatory mechanisms. His experience at a clinical-stage biotechnology company grants a valuable sponsor-side perspective when providing clients with incisive drug landscape analyses and key insights.
Kristen Cordova, Ph.D
Therapy Area Manager
Kristen received her Ph.D. in Molecular Biology from the University of Colorado Anschutz Medical Campus. She has a strong research background that was most recently applied to scientific and medical content creation at Biodesix in lung cancer and melanoma. Kristen has a unique ability to analyze complex data and succinctly report on the most meaningful clinical and commercial implications.
Medical Conference Coverage
In the fast-moving field of Emerging I-O, ONCrg Conference™ reports deliver highly relevant and forward-looking CI from major congresses like AACR, ASCO, ESMO, and SITC. We capture and analyze new clinical and/or preclinical data critical for assessing the potential impact of novel agents and combinations on the future treatment landscape. Our experts personally attend new data presentations, and our syndicated model assures unbiased, comprehensive research while leaving room to customize coverage to a client’s needs.
Expert Advisory Guidance
ONCrg Advisory™ is an open door to ask non-proprietary questions in Emerging I-O and your other subscription areas. Our experts utilize extensive resources and experience to provide extra guidance to inform clients’ key decisions.
Competitive Landscape Analysis
ONCrg Pipeline Strategies™ delivers cutting-edge analysis by mechanism of action for emerging immuno-oncology agents, and includes named drugs in corporate development for unspecified cancer types from preclinical through Phase II. Presentation-style reports are updated quarterly, include pipe- line tables, and provide valuable analytics by subclass and by company.
Monthly Surveillance Reports
ONCrg Sentinel™ provides vigilant monitoring of rapidly evolving scientific, clinical, and commercial activities in Emerging I-O. ONCrg experts identify and analyze events and deliver incisive commentaries to inform subscribers each month and prepare them to respond wisely to ever-changing market conditions.